-
Candel Therapeutics NASDAQ:CADL Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. CAN-2409 is the lead product candidate from the adenovirus platform, and CAN-3110 is the lead product candidate from the HSV platform.
Location: | Website: www.candeltx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
172.1M
Cash
21.45M
Avg Qtr Burn
-7.717M
Short % of Float
7.92%
Insider Ownership
30.85%
Institutional Own.
20.31%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CAN-2409 Details Cancer, Solid tumor/s, Intermediate/high-risk Prostate cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
CAN-2409 Details Cancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer | Phase 2b Data readout | |
CAN-2409 + Valacyclovir w/ SoC Details Pancreatic cancer, Cancer | Phase 2 Data readout | |
CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents Details Lung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 2 Update | |
CAN-3110 Details Solid tumor/s, Cancer, Glioma | Phase 1b Data readout | |
CAN-2409 + Opdivo Details Cancer, Glioma, Solid tumor/s | Failed Discontinued |